Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | CPT1A | P50416 | 4/20 | 0.51 |
| ▸ | CPT1B | Q92523 | 4/20 | 0.51 |
| ▸ | CPT2 | P23786 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | PPARD | Q03181 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 4/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353192 | 0.92 | PPARG (0.62) | MAPTCPT1ACPT1BCPT2PPARG | |
| SCHEMBL6357406 | 0.85 | CPT1A (0.54) | MAPTCPT1ACPT1BCPT2PPARG | |
| SCHEMBL6352803 | 0.82 | CPT1A (0.49) | MAPTCPT1ACPT1BCPT2PPARG | |
| SCHEMBL6359100 | 0.82 | MAPT (0.61) | MAPTTP53 | |
| SCHEMBL15788196 | 0.80 | MAPT (0.61) | MAPTPPARGPPARDPPARATP53 | |
| SCHEMBL6348623 | 0.79 | ALB (0.62) | MAPTPPARGPPARDPPARATP53 | |
| SCHEMBL6352904 | 0.78 | SERPINE1 (0.72) | SERPINE1 | |
| SCHEMBL6359987 | 0.76 | PPARG (0.65) | MAPTCPT1ACPT1BCPT2PPARG | |
| SCHEMBL6351726 | 0.75 | MAPT (0.50) | MAPTCPT1ACPT1BCPT2PPARG | |
| SCHEMBL6352881 | 0.75 | MAPT (0.56) | MAPTCPT1ACPT1BCPT2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | MAPT 4753/4885CPT1A 4114/4885CPT1B 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.